ArticleBMC gastroenterology2025
Overexpression of Protein Kinase C iota as a prognostic marker and its role in oxaliplatin resistance in colorectal cancer.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProtein Kinase C iota (PKCι) has been implicated in cancer progression and chemoresistance, but its prognostic significance in solid tumors remains unclear. This study aimed to evaluate the expression of PKCι in tumor tissues and its association with clinicopathological features, survival outcomes, and chemotherapy response in patients with cancer.
methodsA retrospective analysis was conducted on patients with confirmed cancer diagnoses. Immunohistochemistry (IHC) was used to assess PKCι expression levels in tumor tissues. Kaplan-Meier survival curves and univariate Cox analysis were applied to evaluate the impact of PKCι expression and other clinicopathological variables on overall survival (OS) and progression-free survival (PFS). The association between PKCι expression and chemotherapy resistance, particularly oxaliplatin resistance, was also investigated.
resultsPKCι overexpression was possibly correlated with advanced clinical stage, metastasis, organs involvement, vascular invasion, and perineural invasion. Patients with PKCι overexpression was possibly correlated with oxaliplatin resistance(P = 0.014). Besides, Patients with PKCι overexpression exhibited significantly shorter PFS compared to those with low expression levels (P = 0.0006). Univariate Cox analysis confirmed that metastasis (H.R. = 11.910, P = 0.018) and clinical staging (H.R. = 5.498, P = 0.027) were independent prognostic factors for OS, whereas CEA levels (H.R. = 3.497, P = 0.005) was independent predictors of PFS.
conclusionPKCι overexpression is associated with tumor aggressiveness and chemotherapy resistance, indicating its potential as a prognostic biomarker and therapeutic target in cancer preliminarily.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.